Genomtec SA (DE:4VI)
FRANKFURT:4VI
4VI Stock Chart & Stats
€0.95
-€0.29(-15.16%)
At close: 4:00 PM EST
€0.95
-€0.29(-15.16%)
Day’s Range― - ―
52-Week Range€0.71 - €1.68
Previous CloseN/A
Volume0.00
Average Volume (3M)35.00
Market Cap
€18.75M
Enterprise Value€76.31M
Total Cash (Recent Filing)€2.60M
Total Debt (Recent Filing)€1.78M
Price to Earnings (P/E)―
Beta-0.37
Next Earnings
Oct 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.64
Shares Outstanding17,064,634
10 Day Avg. Volume0
30 Day Avg. Volume35
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)6.21
Price to Sales (P/S)2725.98
P/FCF Ratio-4.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
4VI FAQ
What was Genomtec SA’s price range in the past 12 months?
Genomtec SA lowest stock price was €0.71 and its highest was €1.68 in the past 12 months.
What is Genomtec SA’s market cap?
Genomtec SA’s market cap is €18.75M.
When is Genomtec SA’s upcoming earnings report date?
Genomtec SA’s upcoming earnings report date is Oct 05, 2026 which is in 102 days.
How were Genomtec SA’s earnings last quarter?
Genomtec SA released its earnings results on May 28, 2026. The company reported -€0.034 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.034.
Is Genomtec SA overvalued?
According to Wall Street analysts Genomtec SA’s price is currently Overvalued.
Does Genomtec SA pay dividends?
Genomtec SA does not currently pay dividends.
What is Genomtec SA’s EPS estimate?
Genomtec SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genomtec SA have?
Genomtec SA has 17,064,634 shares outstanding.
What happened to Genomtec SA’s price movement after its last earnings report?
Genomtec SA reported an EPS of -€0.034 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -20%.
Which hedge fund is a major shareholder of Genomtec SA?
Currently, no hedge funds are holding shares in DE:4VI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Genomtec SA
Genomtec S.A., established in 2016 and based in Wroclaw, Poland, is dedicated to the research, development, manufacturing, and global commercialization of advanced molecular diagnostic products. The company's expertise lies in optical systems and isothermal nucleic acid amplification methodologies. A core offering is Genomtec ID, a portable technological device designed for on-the-go genetic diagnostics. This system employs streamlined nucleic acid amplification technology (SNAAT) to detect viruses, bacteria, fungi, and genetic mutations through the analysis of patient biological materials like swabs, urine, saliva, blood, and other bodily fluids. Furthermore, Genomtec has developed Genomtec Tumor, a SNAAT-based solution for identifying neoplastic mutations and those with prognostic value in cancer diagnoses. The company also offers diagnostic kits for COVID-19, including the Genomtec SARS-CoV-2 EvaGreen and Direct-RT-LAMP CE-IVD Kit, which detects SARS-CoV-2 RNA in samples from individuals suspected of infection, and the Genomtec RT-LAMP CE-IVD Duo-Kit, capable of identifying all variants of the SARS-CoV-2 virus.
Technical Analysis
Biomaxima SA
―
Pure Biologics SA
―
Scope Fluidics SA
―
OncoArendi Therapeutics SA
―
Mabion SA
―